This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Tanezumab

Pfizer Inc.

Drug Names(s): Rn624, PF-4383119

Description: PF-4383119 is a humanized monoclonal antibody that blocks nerve growth factor (NGF).

NGF is also thought to have a role in pain, altering the functions of nerve cells that recognize painful stimuli (nociceptors). Tissue damage or inflammation induces high levels of NGF secretion, and in the short term, NGF stimulates the release of chemicals that increase the sensitivity of nociceptors to pain (e.g. substance P, CGRP, histamine). Afterwards, the extra stimulation of NGF receptors may lead to a remodeling of pain pathways, with an increase in the number of nociceptive fibres and pain sensitizing molecules, such as ion channels.

Preclinical models of pain suggest that PF-4383119 demonstrates equal or better efficacy than opiates or NSAIDS. In these preclinical studies, PF-4383119 also had a significantly longer half-life compared to other pain therapeutics.

Deal Structure: PF-4383119 was discovered by Rinat Neuroscience. In November 2004, Genentech and Rinat announced that Genentech had exercised its option under an agreement with Rinat to co-develop and commercialize PF-4383119 on a worldwide basis. Genentech then decided not the pursue the drug and opted back out of the agreement.

In 2006, Pfizer acquired Rinat.

Pfizer and Eli Lilly
In October 2013, Pfizer reported that they have entered into a collaboration agreement with Eli Lilly to jointly develop and globally commercialize tanezumab, which provides that Pfizer and Lilly will equally share product development expenses as well as potential revenues and certain product-related costs.

Under the agreement with Lilly, Pfizer is eligible to receive certain payments from Lilly upon the achievement of specified clinical, regulatory and commercial milestones, including an upfront payment that is contingent upon the parties continuing in the collaboration after receipt of the...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company


Tanezumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug